Last reviewed · How we verify
Fluarix Tetra Vaccine
Fluarix Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
Fluarix Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Influenza prophylaxis in adults and children ≥6 months of age.
At a glance
| Generic name | Fluarix Tetra Vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. Upon intramuscular injection, these viral antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells. This enables the vaccinated individual to recognize and mount a rapid immune response upon exposure to circulating influenza viruses.
Approved indications
- Influenza prophylaxis in adults and children ≥6 months of age
Common side effects
- Injection site soreness
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE (PHASE4)
- Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses (PHASE4)
- Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.
- Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix Tetra Vaccine CI brief — competitive landscape report
- Fluarix Tetra Vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI